JANX • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold JANX in your mock portfolio yet.
Janux Therapeutics is currently loss-making, as reflected in its negative EPS and PE ratio. The figures indicate an early-stage or development-stage biotech profile where profitability is not yet in sight, and investors are relying on future pipeline success rather than current earnings.
The stock trades at $13.76, down 9.1% over the past month and well below its 200-day moving average of $24.18, signaling a longer-term downtrend. The RSI at 56.53 indicates neither overbought nor oversold conditions, suggesting the recent weakness is part of a broader negative trend rather than a short-term technical overshoot.
Alternative data show modest but positive growth in hiring and social media presence, which can indicate ongoing investment in operations and gradual awareness-building. However, absolute levels of web traffic and social following remain relatively small, so these signals are supportive but not strong enough to offset financial and technical weaknesses.
Overall, Janux Therapeutics presents a high-risk profile with a bearish tilt, driven by ongoing losses and a stock price entrenched below its long-term moving average. While hiring growth and slowly improving alternative data are mildly constructive, they do not yet outweigh the negative earnings profile and weak technical setup.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: